- You are
- Patients and relatives
- To be cared for and supported
- Become an expert patient
- Research
First leukemia research center in France
Our themes
Acute lymphoblastic leukemia
Acute myeloblastic leukemia
Myeloproliferative syndromes
Myelodysplastic syndromes
Syndromes predisposing to leukemia
Acquired and constitutional bone marrow failure
The Leukemia Institute in numbers
1stleukemia treatment center in France
16research teams
10clinical services
4medical biology laboratories
Our research teams
Our areas of research
Axis 1: MECHANISMS
Fundamental biology
- Deciphering the heterogeneity of leukemias with a multi-omic approach
- Screening for intrinsic vulnerabilities in leukemias
- Exploring the cellular consequences of therapeutic stress
Axis 2: MICRO-ENVIRONMENT
Stem cells and microenvironment
- Study cellular interactions between leukemia cells, stroma, or immune effectors
- Explore the cellular consequences of therapeutic stress
Axis 3: PRECISION
Therapeutic agents and combinations
- Testing innovative treatments on primary cells or preclinical models
- Identifying promising treatment combinations and validating biomarkers
Axis 4: PREDISPOSITION
Prevention and precision medicine
- Identify patients with predisposing germline conditions
- Conduct longitudinal somatic studies
Axis 5: TRIALS
Early clinical trials
- Developing innovative trials for precision medicine
- Integrating biological data into clinical trials
Axis 6: CARE
Improvement of care pathways
- Implement a post-treatment follow-up program
- Explore quality of life measures, in collaboration with patient associations
Our research projects
DYNHAEMICS Study
Suivi longitudinal à l’échelle uni-cellulaire chez les patients adultes récemment diagnostiqués d’une leucémie aiguë myéloïde traités par chimiothérapie intensive
DREAM Study
Dynamique de réponse aux thérapies non-intensives basées sur l’azacitidine dans les leucémies aiguës myéloïdes.
eTHEMA
La Cohorte de Patients du Centre National de Médecine de Précision sur les Leucémies
Scientific publications
PPARγ agonists promote the resolution of myelofibrosis in preclinical models
Lambert J & al, J Clin Invest, 2021Lire la publication
Developmental interplay between transcriptional alterations and a targetable cytokine signaling dependency in pediatric ETO2::GLIS2 leukemia
Verónica Alonso-Pérez & al, Molecular Cancer, 2024Lire la publication
High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL
Julien Calvo & al, Leukemia, 2025Lire la publicationOur clinical trials
Open-label study to evaluate the long-term safety of BCX9930 monotherapy in patients with paroxysmal nocturnal hemoglobinuria who have previously received BCX9930 in a BioCryst-sponsored study
Open-label study to evaluate the long-term safety of BCX9930 monotherapy in patients with paroxysmal nocturnal hemoglobinuria who have previously received BCX9930 in a BioCryst-sponsored study
Open-label study to evaluate the long-term safety of BCX9930 monotherapy in patients with paroxysmal nocturnal hemoglobinuria who have previously received BCX9930 in a BioCryst-sponsored study
Open-label study to evaluate the long-term safety of BCX9930 monotherapy in patients with paroxysmal nocturnal hemoglobinuria who have previously received BCX9930 in a BioCryst-sponsored study
Cooperative groups
Host foundation and founding members
- Become an expert patient
- To be cared for and supported
- Patients and relatives
